All Drug Discovery articles – Page 5
-
NewsEngineered extracellular vesicles control immune responses
Researchers have engineered new extracellular vesicles that can selectively induce antigen-specific regulatory T cells, possibly leading towards safer, more precise treatments for autoimmune and allergic diseases.
-
ArticlePeptides in practice: what it takes to advance these therapies to clinic
Peptide therapeutics are emerging as a powerful class of medicines capable of targeting diseases that challenge traditional modalities. This article reveals their rising clinical impact and the key development, safety and translational challenges that must be addressed to bring them successfully to patients.
-
NewsNew research aims to make FDA-approved drugs safer for the brain
Life-saving HIV and cancer drugs can carry serious neurological risks, and new funding will help UMBC researchers discover how these medicines damage the brain – which could help to inform safer treatments.
-
NewsNew study identifies genetic weakness in deadly Candida auris fungus
Scientists at the University of Exeter have discovered a genetic process in the deadly hospital fungus Candida auris, which could help to develop new treatments.
-
ArticleWhy patient-derived biology matters for ADC discovery
What can we learn from tumours after they stop responding to treatment? By studying patient tissue directly, researchers are finding new ADC targets that conventional screening often misses.
-
NewsNew method preserves iPS cells for regenerative medicine
Kobe University researchers have developed a new way of freeze induced pluripotent stem cells (iPS cells) directly in their culture dishes without losing viability or pluripotency.
-
NewsScientists discover potential therapy for pancreatic cancer-induced cachexia
University of Houston researchers have identified a key cellular pathway involved in muscle wasting caused by pancreatic cancer, offering new insights into potential therapies.
-
WebinarThe truth about AI in drug discovery: what the experts really think
AI in drug discovery is evolving fast. Join the experts behind today’s real progress as they share what works, what doesn’t and what you need to know next.
-
NewsCBD and THC show anti-cancer effects against ovarian tumours
New research suggests cannabis compounds CBD and THC could offer a new approach to treating ovarian cancer.
-
NewsFertility gene PRDM9 linked to relapse in glioblastoma
A study by University of Sydney scientists has discovered why patients with glioblastoma often relapse, identifying a hidden population of cancer cells that hijack a fertility gene to survive chemotherapy.
-
ArticleThe future of obesity drugs starts in preclinical discovery
Progress in preclinical models and biomarker science is improving early-stage obesity drug development. This article outlines the emerging targets and technologies behind this shift.
-
NewsAI-powered CKD drug ISM4808 licensed for kidney disease therapy
Insilico Medicine has partnered with TaiGen Biotechnology to exclusively license its AI-designed PHD inhibitor, ISM4808, for the treatment of CKD-related anaemia in Greater China.
-
NewsInhibiting DDR1 pathway helps breach pancreatic cancer’s drug barrier
Scientists in Japan have identified a way to weaken the dense fibrotic barrier that prevents drugs from penetrating pancreatic tumours – a promising new strategy that could improve treatment for pancreatic cancer.
-
NewsNew Spheromatrix platform speeds up cancer drug research
Researchers at NYU Abu Dhabi have developed a cheap, paper-based platform that allows tumour models to be grown, frozen and stored for future cancer drug testing – called Spheromatrix.
-
ArticleProtein folding interference: a new path to hard-to-drug targets
Protein folding interference offers access to targets long considered unreachable by traditional drug discovery. By acting on transient folding intermediates, this approach presents a new opportunity to eliminate disease-driving proteins.
-
NewsLife sciences face ‘scientific content crisis’ in AI adoption
A new survey by the Pistoia Alliance reveals a growing ‘scientific content crisis’ in life sciences, showing that incomplete data and weak governance are limiting the accuracy and adoption of AI in research and development.
-
NewsTY1: new experimental drug restores tissue after heart attack
Scientists have developed an experimental RNA-based drug, TY1, that repairs DNA, reduces scar tissue and could lead to new treatments for heart attacks and autoimmune diseases.
-
NewsBits2Bonds: AI system accelerates discovery of RNA delivery polymers
Researchers at LMU Munich have developed Bits2Bonds, the first platform to fuse molecular simulations with machine learning – accelerating the discovery of polymer carriers for therapeutic RNA.
-
NewsAutomated lung organoids to speed up new drug development
Scientists have developed an automated method to grow lung organoids, with the hope of speeding up drug testing, reducing reliance on animal models and helping to develop new personalised treatments.
-
ArticleThe partnership changing the pace of radiopharmaceutical development
A new collaboration between Crown Bioscience and Medicines Discovery Catapult is bringing advanced tumour models together with world-class imaging and radiochemistry to accelerate the development of next-generation radiopharmaceuticals.